Current NDC auxiliary source row compounder:435

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 26436-5473
Product Ndc: 26436-5473
Product Ndc Digits: 264365473
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: BLT Topical Gel
Proprietary Name Suffix: [empty]
Nonproprietary Name: BLT 20/8/2
Dosage Form Name: GEL
Route Name: TOPICAL
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Hybrid Pharma
Establishment Name: Hybrid Pharma
Establishment Fei: [empty]
Substance Name: BENZOCAINE; TETRACAINE; LIDOCAINE
Active Ingredients Info: 200 mg/1 g; 20 mg/1 g; 80 mg/1 g
History Active Ingredients Raw: BENZOCAINE; TETRACAINE; LIDOCAINE
History Active Ingredients Info Raw: 200 mg/1 g; 20 mg/1 g; 80 mg/1 g
History Dosage Raw: GEL
Dea Schedule: [empty]
Package Ndc Raw: 26436-5473-3
Package Ndc: 26436-5473-3
Package Ndc Digits: 2643654733
Package Ndc11: 26436547303
Package Description: 30 g in 1 JAR (26436-5473-3)
Reporting Period Raw: 2026-1
Reporting Period: 2026-1
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:435
Source Row Number: 435
Source Row Hash: d70cdb4a1d3b60d11cfe7ed25fce0d34e89a03cf4faba53f305515f46bd3c6c7
Import Run Id: 20261015T162751Z
Loaded At: 2026-10-15 16:32:20

Exact raw FDA source fields#

{
    "ROUTENAME": "TOPICAL",
    "PRODUCTNDC": "26436-5473",
    "DEASCHEDULE": "",
    "LABELERNAME": "Hybrid Pharma",
    "SUBSTANCENAME": "BENZOCAINE; TETRACAINE; LIDOCAINE",
    "DOSAGEFORMNAME": "GEL",
    "NDCPACKAGECODE": "26436-5473-3",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "BLT Topical Gel",
    "REPORTINGPERIOD": "2026-1",
    "NONPROPRIETARYNAME": "BLT 20/8/2",
    "PACKAGEDESCRIPTION": "30 g in 1 JAR (26436-5473-3) ",
    "ACTIVEINGREDIENTSINFO": "200 mg/1 g; 20 mg/1 g; 80 mg/1 g",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:435
Source Row Number: 435
Status Scope: package
Lookup Ndc: 26436-5473-3
Lookup Ndc Digits: 2643654733
Product Ndc: 26436-5473
Product Ndc Digits: 264365473
Package Ndc: 26436-5473-3
Package Ndc Digits: 2643654733
Package Ndc11: 26436547303
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2026-1
Reporting Period: 2026-1
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: d70cdb4a1d3b60d11cfe7ed25fce0d34e89a03cf4faba53f305515f46bd3c6c7
Import Run Id: 20261015T162751Z
Loaded At: 2026-10-15 16:32:20